Tuesday, 24 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 24 March 2026
News

Most expensive drug out of stock

Posted 24 March 2026 PM

CSL has warned of a temporary global stockout affecting haemophilia B gene therapy Hemgenix, with the supply impacted due to problems in manufacturing.

The news comes mere months after the MSAC supported public funding Hemgenix under the National Blood Program, although at a lower than proposed price. The cost of the therapy has been estimated at AU$5 million per dose.

To see the whole article, please login

Popular

Ex-J&J staffer sued for secrets 'theft'
Who's back in Aust for a new role?
Novo slapped with Warning Letter
$90B time bomb exposed
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home